Thought some my find this interesting. In the short to medium...

Thought some my find this interesting. 

In the short to medium term most of the value of RAC would be within the Priority Review Voucher. This link give you some more info -

https://priorityreviewvoucher.org/#pediatric

To be eligible for a voucher, the drug or vaccine must satisfy the following criteria:

1. Treat a listed disease

2. Contain no active ingredient (including any ester or salt of the active ingredient) that has been approved in any other FDA application.

3. Offer major advances in treatment, or provide treatment where no adequate therapy exists, thus earning priority review on its own merit. In other words, to win a bonus priority review, the treatment must first get its own priority review.

My guess would be criteria 3 would be the biggest challenge, BUT as its a proven drug that passed previous trials, there is an increased likelihood that it may just cross the line. 

What's even of more interest is that in 2018 the voucher was not sold above US$80mil. I.e. should they get it there is a possibility that SP could increase 10x

My own opinion, do your own research...